71 related articles for article (PubMed ID: 1746991)
1. Medical therapy for gastroesophageal reflux disease. Not all treatments are equal!
Fennerty MB; Sampliner RE
Arch Intern Med; 1991 Dec; 151(12):2365-6. PubMed ID: 1746991
[No Abstract] [Full Text] [Related]
2. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
4. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
5. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S
Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996
[TBL] [Abstract][Full Text] [Related]
6. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
7. In support of "step-up therapy" for gastroesophageal reflux disease.
Beck IT
Am J Gastroenterol; 2002 Feb; 97(2):503-4. PubMed ID: 11866309
[No Abstract] [Full Text] [Related]
8. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
Katzka DA; Paoletti V; Leite L; Castell DO
Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
[TBL] [Abstract][Full Text] [Related]
9. Successful drug-specific chronotherapy with the H2 blocker famotidine in the symptomatic relief of gastroesophageal reflux disease.
Humphries TJ; Root JK; Hufnagel K
Ann N Y Acad Sci; 1991; 618():517. PubMed ID: 2006804
[No Abstract] [Full Text] [Related]
10. Empiric therapy for gastroesophageal reflux disease.
Schindlbeck NE; Klauser AG; Voderholzer WA; Müller-Lissner SA
Arch Intern Med; 1995 Sep; 155(16):1808-12. PubMed ID: 7654116
[TBL] [Abstract][Full Text] [Related]
11. The treatment of gastroesophageal reflux disease.
Kaplan B; Koppelo KL
W V Med J; 1994 Dec; 90(12):510-7. PubMed ID: 7863640
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
13. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
Ducrotté P; Guillemot F; Elouaer-Blanc L; Hirschauer C; Thorel JM; Petit A; Hochain P; Michel P; Cortot A; Colin R
Am J Gastroenterol; 1994 May; 89(5):717-21. PubMed ID: 8172144
[TBL] [Abstract][Full Text] [Related]
14. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
[TBL] [Abstract][Full Text] [Related]
15. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
Sontag SJ
Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole may delay the diagnosis of pyloric stenosis.
Shaikh MG; Anderson JM
Acta Paediatr; 2004 Feb; 93(2):283. PubMed ID: 15046292
[No Abstract] [Full Text] [Related]
17. [Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness].
Abidin ZU; Ivashkin VT; Sheptulin AA; Trukhmanov AS; Okhlobystin AV
Klin Med (Mosk); 1999; 77(7):39-42. PubMed ID: 10483164
[TBL] [Abstract][Full Text] [Related]
18. Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children?
Hassall E
Am J Gastroenterol; 1995 Aug; 90(8):1212-20. PubMed ID: 7639217
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring.
Bishop J; Furman M; Thomson M
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):50-5. PubMed ID: 17592364
[TBL] [Abstract][Full Text] [Related]
20. Drug therapy of peptic ulcer disease.
Ching CK; Lam SK
Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
